Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 18/20 | 0.53 |
| ▸ | FPR1 | P21462 | 10/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637096 | 0.87 | ALDH1A1 (0.52) | FPR2 | |
| SCHEMBL5637813 | 0.86 | RAB9A (0.48) | — | |
| SCHEMBL5640321 | 0.82 | FPR1 (0.45) | FPR2FPR1TRPV1 | |
| SCHEMBL5637671 | 0.79 | NPC1 (0.53) | — | |
| SCHEMBL5641964 | 0.76 | FPR2 (0.48) | FPR2 | |
| SCHEMBL5636798 | 0.75 | PREP (0.33) | FPR2FPR1 | |
| SCHEMBL5638327 | 0.75 | NPC1 (0.44) | FPR2FPR1 | |
| SCHEMBL28884238 | 0.74 | NAMPT (0.51) | FPR2FPR1TRPV1 | |
| SCHEMBL23573367 | 0.73 | EPHX2 (0.64) | TRPV1 | |
| SCHEMBL5637810 | 0.73 | LMNA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | FPR2 180/4885FPR1 107/4885TRPV1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.